Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Nucleus RadioPharma secured a Series A extension funding with AstraZeneca investment.
PRIVATEJun 05, 2024•about 2 years ago
Round Type
Series A
DavidsonManufacturingBiotechnologyHealth CarepharmaceuticalsInvestors
University Of MissouriEcho Global Granger Management Mercy HealthFox Chase Cancer CenterEclipse VenturesMayo ClinicGe HealthcareAstra Zeneca
Description
Nucleus RadioPharma announced the closing of a Series A extension round with new investor AstraZeneca, joining existing investors GE Healthcare, Mayo Clinic, and others. The funding will be used to expand development, supply, and commercial manufacturing capabilities to make targeted radiotherapies and theranostics more accessible to patients globally.
Related People
Suggested for you
1 contactVerified contactsNo contacts on file at Nucleus RadioPharma yet.
Funding Insights
Based on industry dataTypical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers